JPWO2021113658A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021113658A5 JPWO2021113658A5 JP2022534348A JP2022534348A JPWO2021113658A5 JP WO2021113658 A5 JPWO2021113658 A5 JP WO2021113658A5 JP 2022534348 A JP2022534348 A JP 2022534348A JP 2022534348 A JP2022534348 A JP 2022534348A JP WO2021113658 A5 JPWO2021113658 A5 JP WO2021113658A5
- Authority
- JP
- Japan
- Prior art keywords
- bacteria
- composition
- species
- russian
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 claims description 85
- 230000001580 bacterial effect Effects 0.000 claims description 47
- 230000001013 cariogenic effect Effects 0.000 claims description 21
- 208000002925 dental caries Diseases 0.000 claims description 17
- 241000894007 species Species 0.000 claims description 16
- 241000711295 Aeria Species 0.000 claims description 14
- 241000186660 Lactobacillus Species 0.000 claims description 10
- 241000194019 Streptococcus mutans Species 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 5
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 5
- 241000960363 Streptococcus infantis Species 0.000 claims description 5
- 241000193987 Streptococcus sobrinus Species 0.000 claims description 5
- 230000001332 colony forming effect Effects 0.000 claims description 4
- 241000194023 Streptococcus sanguinis Species 0.000 claims description 3
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000282836 Camelus dromedarius Species 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000283074 Equus asinus Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000282575 Gorilla Species 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 241000282577 Pan troglodytes Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 241000282842 Lama glama Species 0.000 claims 1
- 241000203719 Rothia dentocariosa Species 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 54
- 241000557476 Streptococcus sanguinis SK36 Species 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- -1 tagalose Polymers 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Description
等価物
当業者は、本明細書に記載された本発明の具体的な実施形態に対する多くの等価物を認識するはずであり、又は、通常行われる実験を用いるだけでそれらを確かめることができるはずである。そのような等価物は、以下の特許請求の範囲によって包含されるものとする。
例えば、本発明は以下の実施形態を包含する：
［実施形態１］ロシア・デントカリオーサ種の細菌、ロシア・アエリア種の細菌、又はこれらの組合せを含む治療有効量の細菌組成物を対象に投与することを含む、対象におけるう蝕を予防する方法。
［実施形態２］細菌組成物が、う蝕原性細菌による酸産生を阻害することによってう蝕を予防する、実施形態１に記載の方法。
［実施形態３］細菌組成物がう蝕原性細菌の増殖を阻害しない、実施形態１又は２に記載の方法。
［実施形態４］う蝕原性細菌が、ストレプトコッカス・ミュータンス種、ストレプトコッカス・インファンティス種、ストレプトコッカス・サングイニスＳＫ３６種、又はストレプトコッカス・ソブリナス種の細菌である、実施形態１から３のいずれかに記載の方法。
［実施形態５］ストレプトコッカス・ミュータンス種の細菌が、ＡＴＣＣ ＵＡ１４０株又はＡＴＣＣ ＵＡ１５９株の細菌である、実施形態４に記載の方法。
［実施形態６］う蝕原性細菌がラクトバチルス属の細菌である、実施形態１から３のいずれかに記載の方法。
［実施形態７］ラクトバチルス属の細菌が、ラクトバチルス・ファーメンタム種及びラクトバチルス・サリバリウス種の細菌である、実施形態６に記載の方法。
［実施形態８］対象がう蝕を発生するリスクを有する、実施形態１から７のいずれかに記載の方法。
［実施形態９］ロシア・デントカリオーサ種の細菌、ロシア・アエリア種の細菌、又はこれらの組合せを含む治療有効量の細菌組成物を対象に投与することを含む、対象におけるう蝕を処置する又はその重症度を低減する方法。
［実施形態１０］細菌組成物が、う蝕原性細菌による酸産生を阻害することによってう蝕を処置する又はその重症度を低減する、実施形態９に記載の方法。
［実施形態１１］細菌組成物がう蝕原性細菌の増殖を阻害しない、実施形態９又は１０に記載の方法。
［実施形態１２］う蝕原性細菌が、ストレプトコッカス・ミュータンス種、ストレプトコッカス・インファンティス種、ストレプトコッカス・サングイニスＳＫ３６種、又はストレプトコッカス・ソブリナス種の細菌である、実施形態９から１１のいずれかに記載の方法。
［実施形態１３］ストレプトコッカス・ミュータンス種の細菌が、ＡＴＣＣ ＵＡ１４０株又はＡＴＣＣ ＵＡ１５９株の細菌である、実施形態１２に記載の方法。
［実施形態１４］う蝕原性細菌がラクトバチルス属の細菌である、実施形態９から１１のいずれかに記載の方法。
［実施形態１５］ラクトバチルス属の細菌が、ラクトバチルス・ファーメンタム種及びラクトバチルス・サリバリウス種の細菌である、実施形態１４に記載の方法。
［実施形態１６］細菌組成物中の細菌の少なくとも５０％が、ロシア・デントカリオーサ種、ロシア・アエリア種、又はこれらの組合せの細菌である、実施形態１から１５のいずれかに記載の方法。
［実施形態１７］細菌組成物中の細菌の少なくとも９０％が、ロシア・デントカリオーサ種、ロシア・アエリア種、又はこれらの組合せの細菌である、実施形態１から１６のいずれかに記載の方法。
［実施形態１８］細菌組成物中の細菌の実質的にすべてが、ロシア・デントカリオーサ種、ロシア・アエリア種、又はこれらの組合せの細菌である、実施形態１から１７のいずれかに記載の方法。
［実施形態１９］細菌組成物が、少なくとも１×１０
６
コロニー形成単位（ＣＦＵ）のロシア・デントカリオーサ種、ロシア・アエリア種、又はこれらの組合せの細菌を含む、実施形態１から１５のいずれかに記載の方法。
［実施形態２０］ロシア属の細菌を含む細菌組成物を対象に投与することを含む、対象におけるう蝕原性細菌による酸産生を阻害する方法。
［実施形態２１］細菌組成物が、ロシア・デントカリオーサ種の細菌、ロシア・アエリアの細菌、及びロシア・ムシラギノーサの細菌から選択される少なくとも１種の細菌を含む、実施形態２０に記載の方法。
［実施形態２２］細菌組成物がう蝕原性細菌の増殖を阻害しない、実施形態２０又は２１に記載の方法。
［実施形態２３］う蝕原性細菌が、ストレプトコッカス・ミュータンス種、ストレプトコッカス・インファンティス種、ストレプトコッカス・サングイニスＳＫ３６種、又はストレプトコッカス・ソブリナス種の細菌である、実施形態２０から２２のいずれかに記載の方法。
［実施形態２４］ストレプトコッカス・ミュータンス種の細菌が、ＡＴＣＣ ＵＡ１４０株又はＡＴＣＣ ＵＡ１５９株の細菌である、実施形態２３に記載の方法。
［実施形態２５］う蝕原性細菌がラクトバチルス属の細菌である、実施形態２０から２２のいずれかに記載の方法。
［実施形態２６］ラクトバチルス属の細菌が、ラクトバチルス・ファーメンタム種及びラクトバチルス・サリバリウス種の細菌である、実施形態２５に記載の方法。
［実施形態２７］対象がう蝕の発生するリスクを有する、実施形態２０から２６のいずれかに記載の方法。
［実施形態２８］細菌組成物が対象におけるう蝕を予防する、実施形態２０から２７のいずれかに記載の方法。
［実施形態２９］対象がう蝕に罹患している、実施形態２０から２６のいずれかに記載の方法。
［実施形態３０］細菌組成物が対象におけるう蝕を処置するはその重症度を低減する、実施形態２９に記載の方法。
［実施形態３１］細菌組成物中の細菌の少なくとも５０％がロシア属の細菌である、実施形態１から３０のいずれかに記載の方法。
［実施形態３２］細菌組成物中の細菌の少なくとも９０％がロシア属の細菌である、実施形態１から３１のいずれかに記載の方法。
［実施形態３３］細菌組成物中の細菌の実質的にすべてがロシア属の細菌である、実施形態１から３２のいずれかに記載の方法。
［実施形態３４］細菌組成物が、少なくとも１×１０
６
コロニー形成単位（ＣＦＵ）のロシア属の細菌を含む、実施形態１から３０のいずれかに記載の方法。
［実施形態３５］細菌組成物が経口投与される、実施形態１から３４のいずれかに記載の方法。
［実施形態３６］細菌組成物が２回以上の用量で投与される、実施形態１から３５のいずれかに記載の方法。
［実施形態３７］対象への２回以上の用量での投与が少なくとも１日隔てられている、実施形態３６に記載の方法。
［実施形態３８］２回以上の用量での投与が少なくとも１週間隔てられている、実施形態３７に記載の方法。
［実施形態３９］細菌組成物が生きた細菌を含む、実施形態１から３８のいずれかに記載の方法。
［実施形態４０］細菌組成物が弱毒化された細菌を含む、実施形態３９に記載の方法。
［実施形態４１］細菌組成物が死滅した細菌を含む、実施形態１から３８のいずれかに記載の方法。
［実施形態４２］う蝕を予防する、処置する、及び／又はその重症度を低減する第２の治療薬を対象に投与することをさらに含む、実施形態１から４１のいずれかに記載の方法。
［実施形態４３］第２の治療薬が、う蝕原性細菌の増殖を阻害する第２の細菌組成物を対象に投与することを含む、実施形態１から４２のいずれかに記載の方法。
［実施形態４４］う蝕原性細菌が、ストレプトコッカス・ミュータンス種、ストレプトコッカス・インファンティス種、ストレプトコッカス・サングイニスＳＫ３６種、又はストレプトコッカス・ソブリナス種の細菌である、実施形態１から４３のいずれかに記載の方法。
［実施形態４５］う蝕原性細菌がラクトバチルス属の細菌である、実施形態１から４３のいずれかに記載の方法。
［実施形態４６］ラクトバチルス属の細菌が、ラクトバチルス・ファーメンタム種及びラクトバチルス・サリバリウス種の細菌である、実施形態４５に記載の方法。
［実施形態４７］プレバイオティクスを対象に投与することをさらに含む、実施形態１から４６のいずれかに記載の方法。
［実施形態４８］プレバイオティクスが、フルクトオリゴ糖、ガラクトオリゴ糖、トランスガラクトオリゴ糖、キシロオリゴ糖、キトオリゴ糖、大豆オリゴ糖、ゲンチオオリゴ糖、イソマルトオリゴ糖、マンノオリゴ糖、マルトオリゴ糖、マンナンオリゴ糖、ラクツロース、ラクトスクロース、パラチノース、グリコシルスクロース、グアーガム、アラビアゴム、タガロース、アミロース、アミロペクチン、ペクチン、キシラン、又はシクロデキストリンである、実施形態４７に記載の方法。
［実施形態４９］対象が哺乳動物である、実施形態１から４８のいずれかに記載の方法。
［実施形態５０］哺乳動物が、イヌ、ネコ、ウシ、ウマ、ブタ、ロバ、ヤギ、ラクダ、マウス、ラット、モルモット、ヒツジ、ラマ、サル、ゴリラ、チンパンジー又はヒトからなる群から選択される、実施形態４９に記載の方法。
［実施形態５１］哺乳動物がヒトである、実施形態５０に記載の方法。
［実施形態５２］ヒトが子供である、実施形態５１に記載の方法。
Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. It is. Such equivalents are intended to be covered by the following claims.
For example, the invention encompasses the following embodiments:
[Embodiment 1] Preventing dental caries in a subject, comprising administering to the subject a therapeutically effective amount of a bacterial composition comprising bacteria of the species Dentocariosa russianus, bacteria of the species Aeria russia, or a combination thereof. Method.
[Embodiment 2] The method of Embodiment 1, wherein the bacterial composition prevents caries by inhibiting acid production by cariogenic bacteria.
[Embodiment 3] The method according to Embodiment 1 or 2, wherein the bacterial composition does not inhibit the growth of cariogenic bacteria.
[Embodiment 4] Any one of Embodiments 1 to 3, wherein the cariogenic bacteria are Streptococcus mutans species, Streptococcus infantis species, Streptococcus sanguinis SK36 species, or Streptococcus sobrinus species. Method described.
[Embodiment 5] The method according to Embodiment 4, wherein the Streptococcus mutans species bacterium is an ATCC UA140 strain or an ATCC UA159 strain.
[Embodiment 6] The method according to any one of Embodiments 1 to 3, wherein the cariogenic bacterium is a bacterium of the genus Lactobacillus.
[Embodiment 7] The method according to Embodiment 6, wherein the Lactobacillus bacteria are Lactobacillus fermentum species and Lactobacillus salivarius species.
[Embodiment 8] The method according to any one of Embodiments 1 to 7, wherein the subject has a risk of developing dental caries.
[Embodiment 9] Treating dental caries in a subject, comprising administering to the subject a therapeutically effective amount of a bacterial composition comprising bacteria of the species Dentocariosa Russianis, bacteria of the species Aeria Russianus, or a combination thereof. or a method of reducing its severity.
[Embodiment 10] The method of embodiment 9, wherein the bacterial composition treats or reduces the severity of dental caries by inhibiting acid production by cariogenic bacteria.
[Embodiment 11] The method according to Embodiment 9 or 10, wherein the bacterial composition does not inhibit the growth of cariogenic bacteria.
[Embodiment 12] Any one of Embodiments 9 to 11, wherein the cariogenic bacteria are Streptococcus mutans species, Streptococcus infantis species, Streptococcus sanguinis SK36 species, or Streptococcus sobrinus species. Method described.
[Embodiment 13] The method according to Embodiment 12, wherein the Streptococcus mutans species bacterium is an ATCC UA140 strain or an ATCC UA159 strain.
[Embodiment 14] The method according to any one of Embodiments 9 to 11, wherein the cariogenic bacterium is a bacterium of the genus Lactobacillus.
[Embodiment 15] The method according to Embodiment 14, wherein the bacteria of the genus Lactobacillus are bacteria of the species Lactobacillus fermentum and Lactobacillus salivarius.
[Embodiment 16] The method according to any of embodiments 1 to 15, wherein at least 50% of the bacteria in the bacterial composition are bacteria of the species Russian dentocariosa, the species Aeria Russian, or a combination thereof. .
[Embodiment 17] The method according to any of embodiments 1 to 16, wherein at least 90% of the bacteria in the bacterial composition are bacteria of the Russian dentocariosa species, the Russian aeria species, or a combination thereof. .
[Embodiment 18] The method according to any one of embodiments 1 to 17, wherein substantially all of the bacteria in the bacterial composition are bacteria of the Russian dentocariosa species, the Russian aeria species, or a combination thereof. Method.
[Embodiment 19] Any of embodiments 1 to 15, wherein the bacterial composition comprises at least 1 x 10 colony forming units (CFU) of bacteria of Russian dentocariosa species, Russian aeria species, or a combination thereof. Method described in Crab.
[Embodiment 20] A method for inhibiting acid production by cariogenic bacteria in a subject, the method comprising administering to the subject a bacterial composition containing a bacterium belonging to the genus Russian.
[Embodiment 21] The method according to Embodiment 20, wherein the bacterial composition comprises at least one type of bacteria selected from bacteria of the species Russian dentocariosa, bacteria of Russian aeria, and bacteria of Russian mucilaginosa. .
[Embodiment 22] The method according to Embodiment 20 or 21, wherein the bacterial composition does not inhibit the growth of cariogenic bacteria.
[Embodiment 23] Any one of Embodiments 20 to 22, wherein the cariogenic bacteria are Streptococcus mutans species, Streptococcus infantis species, Streptococcus sanguinis species SK36, or Streptococcus sobrinus species. Method described.
[Embodiment 24] The method according to Embodiment 23, wherein the Streptococcus mutans species bacterium is an ATCC UA140 strain or an ATCC UA159 strain.
[Embodiment 25] The method according to any one of Embodiments 20 to 22, wherein the cariogenic bacterium is a bacterium of the genus Lactobacillus.
[Embodiment 26] The method according to Embodiment 25, wherein the bacteria of the genus Lactobacillus are bacteria of the species Lactobacillus fermentum and Lactobacillus salivarius.
[Embodiment 27] The method according to any one of Embodiments 20 to 26, wherein the subject has a risk of developing dental caries.
[Embodiment 28] The method of any of embodiments 20-27, wherein the bacterial composition prevents caries in the subject.
[Embodiment 29] The method according to any one of Embodiments 20 to 26, wherein the subject is suffering from dental caries.
[Embodiment 30] The method of embodiment 29, wherein the bacterial composition treats or reduces the severity of dental caries in the subject.
[Embodiment 31] The method according to any of embodiments 1 to 30, wherein at least 50% of the bacteria in the bacterial composition are bacteria of the genus Russi.
[Embodiment 32] The method according to any of embodiments 1 to 31, wherein at least 90% of the bacteria in the bacterial composition are bacteria of the genus Russi.
[Embodiment 33] The method according to any one of Embodiments 1 to 32, wherein substantially all of the bacteria in the bacterial composition are bacteria of the genus Rossi.
[Embodiment 34] The method of any of embodiments 1 to 30, wherein the bacterial composition comprises at least 1 x 106 colony forming units (CFU) of bacteria of the genus Russi.
[Embodiment 35] The method according to any of embodiments 1 to 34, wherein the bacterial composition is administered orally.
[Embodiment 36] The method of any of embodiments 1-35, wherein the bacterial composition is administered in two or more doses.
[Embodiment 37] The method of Embodiment 36, wherein the administration of the two or more doses to the subject is at least one day apart.
[Embodiment 38] The method of Embodiment 37, wherein the administration of the two or more doses is separated by at least one week.
[Embodiment 39] The method of any of embodiments 1-38, wherein the bacterial composition comprises live bacteria.
[Embodiment 40] The method of embodiment 39, wherein the bacterial composition comprises attenuated bacteria.
[Embodiment 41] The method of any of embodiments 1 to 38, wherein the bacterial composition comprises killed bacteria.
[Embodiment 42] The method of any of Embodiments 1 to 41, further comprising administering to the subject a second therapeutic agent that prevents, treats, and/or reduces the severity of dental caries. .
[Embodiment 43] The method according to any one of Embodiments 1 to 42, wherein the second therapeutic agent comprises administering to the subject a second bacterial composition that inhibits the growth of cariogenic bacteria.
[Embodiment 44] Any one of Embodiments 1 to 43, wherein the cariogenic bacteria are Streptococcus mutans species, Streptococcus infantis species, Streptococcus sanguinis species SK36, or Streptococcus sobrinus species. Method described.
[Embodiment 45] The method according to any one of Embodiments 1 to 43, wherein the cariogenic bacterium is a bacterium of the genus Lactobacillus.
[Embodiment 46] The method according to Embodiment 45, wherein the bacteria of the genus Lactobacillus are bacteria of the species Lactobacillus fermentum and Lactobacillus salivarius.
[Embodiment 47] The method according to any of Embodiments 1 to 46, further comprising administering a prebiotic to the subject.
[Embodiment 48] The prebiotics are fructooligosaccharides, galactooligosaccharides, transgalactooligosaccharides, xylooligosaccharides, chitooligosaccharides, soybean oligosaccharides, gentiooligosaccharides, isomaltooligosaccharides, mannooligosaccharides, maltooligosaccharides, mannanoligosaccharides, lactulose, lactulose 48. The method of embodiment 47, which is sucrose, palatinose, glycosylsucrose, guar gum, gum arabic, tagalose, amylose, amylopectin, pectin, xylan, or cyclodextrin.
[Embodiment 49] The method according to any one of Embodiments 1 to 48, wherein the subject is a mammal.
[Embodiment 50] The mammal is selected from the group consisting of a dog, cat, cow, horse, pig, donkey, goat, camel, mouse, rat, guinea pig, sheep, llama, monkey, gorilla, chimpanzee or human. 50. The method of embodiment 49.
[Embodiment 51] The method of embodiment 50, wherein the mammal is a human.
[Embodiment 52] The method of embodiment 51, wherein the human is a child.
Claims (32)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944717P | 2019-12-06 | 2019-12-06 | |
| US62/944,717 | 2019-12-06 | ||
| PCT/US2020/063343 WO2021113658A1 (en) | 2019-12-06 | 2020-12-04 | Methods and compositions of preventing and treating dental caries |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514002A JP2023514002A (en) | 2023-04-05 |
| JPWO2021113658A5 true JPWO2021113658A5 (en) | 2023-12-12 |
Family
ID=76208923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534348A Pending JP2023514002A (en) | 2019-12-06 | 2020-12-04 | Methods and compositions for preventing and treating dental caries |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11246895B2 (en) |
| JP (1) | JP2023514002A (en) |
| CN (1) | CN115243696A (en) |
| CA (1) | CA3163891A1 (en) |
| IL (1) | IL293620A (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
| US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| IL293620A (en) | 2019-12-06 | 2022-08-01 | Forsyth Dental Infirmary For Children | Methods and compositions of preventing and treating dental caries |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133875A (en) * | 1978-02-23 | 1979-01-09 | Forsyth Dental Infirmary For Children | Method of controlling dental caries with streptococcus mutans mutant strains |
| WO2012028759A2 (en) * | 2010-08-31 | 2012-03-08 | Centro Superior De Investigación En Salud Pública (Csisp) | Anticaries compositions and probiotics/prebiotics |
| JP6241610B2 (en) * | 2014-02-21 | 2017-12-06 | 学校法人大阪歯科大学 | Oral composition and method for treating periodontal disease in animals |
| JP2018515426A (en) * | 2015-03-12 | 2018-06-14 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | Bacterial composition and method of use thereof |
| WO2021113658A1 (en) | 2019-12-06 | 2021-06-10 | Forsyth Dental Infirmary For Children | Methods and compositions of preventing and treating dental caries |
| IL293620A (en) | 2019-12-06 | 2022-08-01 | Forsyth Dental Infirmary For Children | Methods and compositions of preventing and treating dental caries |
-
2020
- 2020-12-04 IL IL293620A patent/IL293620A/en unknown
- 2020-12-04 JP JP2022534348A patent/JP2023514002A/en active Pending
- 2020-12-04 CA CA3163891A patent/CA3163891A1/en active Pending
- 2020-12-04 CN CN202080095830.0A patent/CN115243696A/en active Pending
- 2020-12-11 US US17/119,933 patent/US11246895B2/en active Active
-
2022
- 2022-01-13 US US17/575,160 patent/US11872255B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021113658A5 (en) | ||
| EP1629850B1 (en) | Nutritional composition comprising indigestible oligosaccharides | |
| Çaglar et al. | A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli | |
| Bytzer et al. | Treatment of Helicobacter pylori | |
| Gendron et al. | The oral cavity as a reservoir of bacterial pathogens for focal infections | |
| HRP20210208T1 (en) | Pharmaceutical composition and administrations thereof | |
| CA2416120A1 (en) | Methods and formulations with probiotic microorganisms and medicaments | |
| McLoughlin et al. | Therapy of Helicobacter pylori | |
| ITFI990051A1 (en) | PHARMACEUTICAL COMPOSITION BASED ON LACTIC FERMENTS AND NON-ABSORBABLE CARBOHYDRATIN CONTAINING A CALCIUM SALT AND AN ALUMINUM SALT | |
| Velusamy et al. | Human lactoferrin protects against Streptococcus mutans‐induced caries in mice | |
| JP2017501235A5 (en) | ||
| EA022204B1 (en) | Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum | |
| JP2010505824A5 (en) | ||
| NO980071L (en) | Use of indigestible oligosaccharides to treat and prevent otitis media in humans | |
| CN113633666B (en) | Probiotic microecological preparation for treating oral halitosis and inflammation, and preparation method and application thereof | |
| WO2009092810A2 (en) | Single pharmaceutical composition containing antibiotics and probiotics | |
| Kryuchko et al. | An open-label study to evaluate the effects of Streptococcus salivarius K12 given as a powder formula to prevent respiratory infections in young children | |
| Cannon et al. | Pediatric Oral Systemic Health: From Fetus to Adolescence | |
| Resch et al. | Prophylactic use of the probiotic strain lactobacillus casei rhamnosus as part of a triple anti-infective regimen in very preterm infants during neonatal intensive care | |
| Köymen et al. | Effect of probiotics on the formation of dental caries. | |
| Linfante et al. | Journal of Clinical & Experimental Dermatology Research | |
| Benchimol et al. | Safety issues of probiotic ingestion | |
| Sahgal et al. | Potential oral health friend-Probiotics | |
| CODE | Oral Probiotics on the Horizon: A Review | |
| Petropoulou | Teeth and tongue discolouration: 3 case reports |